News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
250,817 Results
Type
Article (11967)
Company Profile (29)
Press Release (238819)
Multimedia
Podcasts (17)
Webinars (3)
Section
Business (76507)
Career Advice (1074)
Deals (14555)
Drug Delivery (33)
Drug Development (35332)
Employer Resources (38)
FDA (6096)
Job Trends (5844)
News (129741)
Policy (9675)
Tag
Academia (762)
Academic (1)
Accelerated approval (4)
Adcomms (14)
Allergies (80)
Alliances (10452)
ALS (70)
Alzheimer's disease (700)
Antibody-drug conjugate (ADC) (137)
Approvals (6301)
Artificial intelligence (209)
Autoimmune disease (57)
Automation (17)
Bankruptcy (97)
Best Places to Work (5208)
BIOSECURE Act (2)
Biosimilars (96)
Biotechnology (22)
Bladder cancer (111)
Brain cancer (26)
Breast cancer (365)
Cancer (2573)
Cardiovascular disease (196)
Career advice (851)
Career pathing (10)
CAR-T (117)
CDC (12)
Cell therapy (321)
Cervical cancer (27)
Clinical research (32043)
Collaboration (697)
Company closure (1)
Compensation (929)
Complete response letters (12)
COVID-19 (989)
CRISPR (38)
C-suite (248)
Cystic fibrosis (63)
Data (3289)
Denatured (1)
Depression (55)
Diabetes (247)
Diagnostics (2434)
Digital health (17)
Diversity (2)
Diversity, equity & inclusion (7)
Drug discovery (93)
Drug pricing (45)
Drug shortages (11)
Duchenne muscular dystrophy (113)
Earnings (57953)
Editorial (16)
Employer branding (5)
Employer resources (33)
Events (40809)
Executive appointments (462)
FDA (7654)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (3)
Frontotemporal dementia (9)
Funding (637)
Gene editing (79)
Generative AI (12)
Gene therapy (249)
GLP-1 (478)
Government (1437)
Grass and pollen (5)
Guidances (348)
Healthcare (7378)
HIV (34)
Huntington's disease (16)
IgA nephropathy (38)
Immunology and inflammation (140)
Immuno-oncology (7)
Indications (34)
Infectious disease (1106)
Inflammatory bowel disease (92)
Inflation Reduction Act (3)
Influenza (46)
Intellectual property (66)
Interviews (193)
IPO (9305)
IRA (15)
Job creations (981)
Job search strategy (745)
Kidney cancer (13)
Labor market (38)
Layoffs (184)
Leadership (12)
Legal (1736)
Liver cancer (49)
Longevity (4)
Lung cancer (398)
Lymphoma (202)
Machine learning (12)
Management (13)
Manufacturing (246)
MASH (94)
Medical device (5304)
Medtech (5316)
Mergers & acquisitions (5869)
Metabolic disorders (624)
Multiple sclerosis (82)
NASH (9)
Neurodegenerative disease (100)
Neuropsychiatric disorders (26)
Neuroscience (1239)
NextGen: Class of 2025 (2268)
Non-profit (1485)
Now hiring (15)
Obesity (283)
Opinion (82)
Ovarian cancer (75)
Pain (81)
Pancreatic cancer (92)
Parkinson's disease (131)
Partnered (7)
Patents (142)
Patient recruitment (160)
Peanut (37)
People (10028)
Pharmaceutical (12)
Pharmacy benefit managers (9)
Phase I (8813)
Phase II (13687)
Phase III (12145)
Pipeline (2160)
Policy (54)
Postmarket research (1268)
Preclinical (3020)
Press Release (14)
Prostate cancer (135)
Psychedelics (23)
Radiopharmaceuticals (131)
Rare diseases (325)
Real estate (1170)
Recruiting (16)
Regulatory (8215)
Reports (26)
Research institute (745)
Resumes & cover letters (198)
Rett syndrome (11)
RNA editing (5)
RSV (46)
Schizophrenia (89)
Series A (91)
Series B (78)
Service/supplier (2)
Sickle cell disease (45)
Special edition (13)
Spinal muscular atrophy (55)
Sponsored (16)
Startups (822)
State (1)
Stomach cancer (6)
Supply chain (53)
Tariffs (25)
The Weekly (16)
Vaccines (432)
Venture capital (27)
Weight loss (188)
Women's health (18)
Worklife (4)
Date
Today (185)
Last 7 days (531)
Last 30 days (1807)
Last 365 days (19810)
2025 (16403)
2024 (18406)
2023 (17837)
2022 (21574)
2021 (22719)
2020 (20351)
2019 (17975)
2018 (12805)
2017 (12137)
2016 (10409)
2015 (12683)
2014 (9077)
2013 (6615)
2012 (7212)
2011 (7510)
2010 (6715)
Location
Africa (288)
Alabama (28)
Alaska (1)
Arizona (81)
Arkansas (6)
Asia (15144)
Australia (2328)
California (6109)
Canada (1544)
China (553)
Colorado (231)
Connecticut (254)
Delaware (211)
Europe (35665)
Florida (725)
Georgia (149)
Hawaii (2)
Idaho (19)
Illinois (432)
India (23)
Indiana (241)
Iowa (11)
Japan (246)
Kansas (55)
Kentucky (16)
Louisiana (11)
Maine (36)
Maryland (665)
Massachusetts (4412)
Michigan (116)
Minnesota (289)
Mississippi (2)
Missouri (62)
Montana (15)
Nebraska (5)
Nevada (66)
New Hampshire (53)
New Jersey (1593)
New Mexico (11)
New York (1453)
North Carolina (620)
North Dakota (2)
Northern California (2905)
Ohio (152)
Oklahoma (6)
Oregon (15)
Pennsylvania (1068)
Puerto Rico (5)
Rhode Island (18)
South America (435)
South Carolina (14)
Southern California (2345)
Tennessee (71)
Texas (869)
United States (20374)
Utah (119)
Virginia (127)
Washington D.C. (34)
Washington State (499)
West Virginia (2)
Wisconsin (70)
250,817 Results for "4".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
4DMT Sends Eye Disease Asset’s Asia Rights to Otsuka for $85M Upfront
Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a VEGF-C inhibitory RNAi with Regeneron’s Eylea into a single ocular injection.
October 31, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Modular Medical Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
September 30, 2025
·
4 min read
Press Releases
Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET
October 22, 2025
·
2 min read
Press Releases
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
October 31, 2025
·
8 min read
Huntington’s disease
4 Huntington’s Therapies Chasing UniQure
Last month, “historic positive results” from uniQure’s gene therapy snapped the Huntington’s community out of years of failure. As the biotech prepares to submit for FDA approval,
BioSpace
looks at four more candidates on the near horizon.
October 27, 2025
·
6 min read
·
Heather McKenzie
Press Releases
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
October 14, 2025
·
9 min read
Press Releases
Alzheon Announces Peer-Reviewed Scientific Publication of Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease
October 15, 2025
·
12 min read
Regulatory
6 FDA Decisions To Watch For in Q4
From more than 30 target action dates in the last three months of the year,
BioSpace
has narrowed the list to six regulatory decisions that could have far-reaching implications for biopharma and patients.
September 29, 2025
·
9 min read
·
Tristan Manalac
Press Releases
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 4, 2025
September 5, 2025
·
1 min read
Press Releases
Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 4, 2025
September 5, 2025
·
4 min read
1 of 25,082
Next
